Navigation Links
IsoPlexis Obtains Exclusive License to Breakthrough Single-Cell Metabolomics Analysis Technologies From Dr. James Heath’s Lab at Caltech
Date:3/27/2017

IsoPlexis Corporation (IsoPlexis), a venture capital-funded life sciences company dedicated to accelerating the fight against cancer, autoimmune disease and more through a single-cell precision engineering platform, today announced it has received an exclusive license to the single-cell metabolomics and proteomics analysis platform developed in the laboratory of Dr. James Heath at the California Institute of Technology, a pioneer in applying chemical physics to biological problems.

Dr. James Heath’s new inventions enable detection of multiple types of metabolite information from single cells, a capability that aligns well with the IsoCode technology, previously referred to as the SCBC (single-cell barcode chip) solution and the foundation of IsoPlexis’ technologies.

The metabolomics analysis platform provides the ability to track novel metabolite biomarkers involved in the progression of various cancers. The technology’s ability to monitor glioblastoma progression has been detailed in peer-reviewed journals, such as the Journal of the American Chemical Society (JACS).

Sean Mackay, IsoPlexis’ Chief Executive Officer, said, “Dr. Heath’s metabolomics innovations provide yet another critical source of novel information to help clinicians understand the progression of cancer in subsets of cells. Working with a pioneering technical institution like Caltech and developing these highly precise detection solutions with Dr. Heath is just one example of how we’re working to accelerate the fight against cancer.”

Dr. James Heath, Elizabeth W. Gilloon Professor of Chemistry at Caltech, was named one of the seven most powerful innovators of the world by Forbes magazine in 2009. Previously, he founded the California NanoSystems Institute at UCLA and was awarded the prestigious Feynman Prize in Nanotechnology as the co-architect of the first quantum-based, molecular computer switch.

More recently, Dr. Heath has applied his expertise in chemical physics and nanotechnologies to advancing the field of translational medicine, with a specific focus on detecting early stages of resistance in cancers and harnessing the power of the immune system to fight cancer. His breakthrough single-cell analysis platform advances the rapidly growing field of metabolomics, which is seen as critical to developing personalized oncology treatments and monitoring cancer progression. Dr. Heath also sits on the IsoPlexis Board of Directors and Scientific Advisory Board.

Dr. James Heath said, “Several metabolic processes are highly elevated during many transitions from health to disease, and some metabolic signals can even play roles in suppressing anti-cancer immune responses. However, metabolites are small molecules and, unlike proteins, aren’t easily connected to the genetic code. The ability to monitor both metabolites and proteins from the same single cells allows us to begin establishing such connections. Adding additional engineering innovation to the IsoCode technology uniquely positions IsoPlexis to help advance precision medicine, and I am excited we are working together to address some of today’s toughest problems.”

ABOUT ISOPLEXIS:
IsoPlexis is a life sciences company committed to advancing groundbreaking research and therapeutic development in immunology, oncology and other emerging disease areas. The IsoPlexis cellular response analysis platform was developed by scientific leaders at Yale and Caltech. By isolating single immune cells and analyzing their functional omic response, the platform can assess safety and efficacy of therapeutics and monitor disease progression, enabling improved therapeutic development and patient outcomes. Through collaborations with leading pharmaceutical companies and academic labs, the IsoPlexis technology is improving the targeting of breakthrough treatments. The venture capital-funded Yale spinout is headquartered in Branford, Connecticut. For additional information on IsoPlexis, visit http://www.isoplexis.com or email info(at)isoplexis(dot)com.

Read the full story at http://www.prweb.com/releases/2017/03/prweb14187610.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. IsoPlexis Awarded NIH SBIR Grant to Develop Cellular Analysis Platform to Diagnose and Monitor Alzheimer’s
2. GraftWorx Obtains a Pioneer of Sensor Technology and a Key Leader in MEMS
3. Sinovac Obtains Clinical Trial Approval for Sabin-IPV Candidate
4. DS Biopharma Obtains a Granted Patent Covering the Use of DS102 to Treat Fatty Liver Disorders
5. Kultevat obtains license of gene switch technology
6. Avexegen Therapeutics Announces Exclusive License Agreement with Children’s Hospital Los Angeles
7. ThermaGenix, Inc. Announces Start-up and Exclusive Licenses from Brandeis University
8. Immunomedics Enters into Exclusive Global Licensing Agreement with Seattle Genetics for Sacituzumab Govitecan (IMMU-132) with Potential Payments of up to Approximately $2 Billion, Plus Royalties
9. Collective Medical Technologies Edie (a.k.a. PreManage ED) Solution is Exclusively Endorsed by the American College of Emergency Physicians
10. AxioMed Announces 15-year Exclusive Worldwide License on Proprietary Viscoelastic Material with the patent holder DSM
11. Pillar Clinical Research Selects Verified Clinical Trials As Exclusive Provider To Reduce Professional Subjects From Duplicate Enrollment In Their Clinical Trials.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 12, 2017 , ... DuPont Pioneer and recently formed CasZyme, ... into a multiyear collaboration to identify and characterize novel CRISPR-Cas nucleases. The goal ... editing across all applications. , Under the terms of the agreement, Pioneer will ...
(Date:10/11/2017)... ... October 11, 2017 , ... At ... Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief research scientist ... has been selected for membership in ARCS Alumni Hall of Fame . ...
(Date:10/11/2017)...  VMS BioMarketing, a leading provider of patient support solutions, ... Educator (CNE) network, which will launch this week. The VMS ... care professionals to enhance the patient care experience by delivering ... health care professionals to help women who have been diagnosed ... ...
(Date:10/10/2017)... ... ... San Diego-based team building and cooking events company, Lajollacooks4u, has unveiled a ... new look is part of a transformation to increase awareness, appeal to new markets ... It will also expand its service offering from its signature gourmet cooking classes and ...
Breaking Biology Technology:
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities ... (physiological and behavioral), by technology (fingerprint, AFIS, iris recognition, ... recognition, and others), by end use industry (government and ... immigration, financial and banking, and others), and by region ... , Asia Pacific , and ...
Breaking Biology News(10 mins):